HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe

被引：0
|
作者：
Sonnet, Miriam
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ribociclib effective in HR+, HER2– breast cancer
    Sidaway P.
    Nature Reviews Clinical Oncology, 2018, 15 (9) : 532 - 532
  • [2] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer
    Anand A. Dalal
    Patrick Gagnon-Sanschagrin
    Rebecca Burne
    Annie Guérin
    Geneviève Gauthier
    Tania Small
    Polly Niravath
    Advances in Therapy, 2018, 35 : 768 - 778
  • [3] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [4] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [5] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
    Wang, Wei
    Wu, Jiayi
    Chen, Keyu
    Wang, Xiaojia
    Shao, Xiying
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [6] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
    Hope S. Rugo
    Adam Brufsky
    Xianchen Liu
    Benjamin Li
    Lynn McRoy
    Connie Chen
    Rachel M. Layman
    Massimo Cristofanilli
    Mylin A. Torres
    Giuseppe Curigliano
    Richard S. Finn
    Angela DeMichele
    npj Breast Cancer, 8
  • [7] Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Joanne L. Blum
    Caroline DiCristo
    David Gordon
    Meghan S. Karuturi
    David Oubre
    Erin Jepsen
    Juan Cuevas
    Shailendra Lakhanpal
    Monica Z. Montelongo
    Zhe Zhang
    Joseph C. Cappelleri
    Yao Wang
    Debu Tripathy
    Breast Cancer Research and Treatment, 2024, 203 : 463 - 475
  • [8] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
    Connie Kang
    Targeted Oncology, 2024, 19 : 289 - 296
  • [9] Impact of molecular subtype and race on HR+, HER2− breast cancer survival
    Sonya Reid
    Diane Haddad
    Ann Tezak
    Anne Weidner
    Xuefeng Wang
    Brian Mautz
    Jaleesa Moore
    Sydney Cadiz
    Yuwei Zhu
    Wei Zheng
    Ingrid A. Mayer
    Xiao-ou Shu
    Tuya Pal
    Breast Cancer Research and Treatment, 2021, 189 : 845 - 852
  • [10] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
12345